<DOC>
	<DOC>NCT01423253</DOC>
	<brief_summary>Lurasidone HCl is a compound that is a candidate for the treatment of major depressive with mixed features.This clinical study is designed to test how well Lurasidone works to treat major depressive disorder with mixed features over time.</brief_summary>
	<brief_title>Major Depressive Disorder With Mixed Features - Extension</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>Lurasidone Hydrochloride</mesh_term>
	<criteria>Subject provides written informed consent and is willing and able to comply with the protocol in the opinion of the Investigator. Subject has completed 6 weeks of treatment in Study D1050304 (NCT#01421134) or Study D1050305 (NCT#01423240). Subject is judged by the Investigator to be suitable for participation in a 12week clinical trial involving openlabel lurasidone treatment and is able to comply with the protocol in the opinion of the Investigator. Subject answers "yes" to "Suicidal Ideation" Item 4 or 5 on the CSSRS (at time of evaluation) at baseline (Day 43 in Study D1050304 or D1050305). Subject is considered by the Investigator to be at imminent risk of suicide or injury to self, others, or property.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Depression</keyword>
	<keyword>Lurasidone</keyword>
	<keyword>Latuda</keyword>
</DOC>